Keywords: Dendreon, Provenge, USA, Medicare, CMS, Prostate cancer

US MEDAC panel review backs Dendreon’s prostate cancer drug efficacy Provenge for Medicare

Article | 18 November 2010

Print This

The USA’s Dendreon (Nasdaq: DNDN) says the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) reviewed the impact ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in